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Background: The aim of the study was to evaluate the concentration of proteolytic enzymes, MMP-2 and MMP-9,
and their tissue inhibitors, TIMP-1 and TIMP-2, in the blood of patients with benign and malignant pancreatic
tumors.
Methods: MMP-2, MMP-9, TIMP-1, and TIMP-2 were evaluated in the patients with benign and malignant
pancreatic tumors before surgery and in the 30-day follow-up. The study covered 134 patients aged 54 to 76 years,
who were divided into groups by TNM staging.
Results: Before the operation, the highest mean concentration of MMP-2 was found in patients with unresectable
cancer, whereas the highest level of MMP-9 was in patients with resectable cancer. The highest level of TIMP-1 was
noted in patients with inflammatory tumors. In 1 month following the operation, the highest level of MMP-2 was
also in patients with unresectable cancer and the highest level of TIMP-2 in patients with inflammatory tumors.
Conclusions: The evaluation of the level of the studied cytokines in the pancreatic tumor patients can be
diagnostically significant in the differentiation of benign and malignant changes. The changes in the levels of the
studied enzymes and their inhibitors can have a prognostic value in the clinical severity of pancreatic cancer.
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Is solid tumor of the pancreas a malignant or benign le-
sion? This simple question is not easy to answer.
Up to now, the most effective method of treating a pan-
creatic tumor is its early radical surgical removal. How-
ever, the early diagnosis of malignant tumors still remains
an unsolved problem, which hampers a successful recov-
ery. Despite perfect diagnostic methods for detecting the
lesion as malignant or benign, the 100% certain method
which could confirm the malignancy of a tumor before
surgery does not exist. If a tumor is diagnosed as not ma-
lignant prior to surgery, aggressive surgical treatment,
which is usually accompanied with a number of complica-
tions, including death, can be avoided [1].* Correspondence: jacek.smigielski@umed.lodz.pl
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reproduction in any medium, provided the orThe popularization of fine needle biopsy as a diagnostic
tool to differentiate benign and malignant changes was
highly emphasized many years ago [2]. However, this
method can often provide misleading negative results.
Although X-ray imaging can quite precisely denote the
position of a tumor, the question posed in the introduc-
tion still remains unanswered. In future, the early differ-
ential diagnosis of tumors should be rather connected
with specific biochemical and molecular markers.
The pancreas is an endocrine gland, well supplied with
blood, which facilitates easy transfusion through the per-
meable walls of the blood vessels [3]. This blood perfusion
is important for proper metabolism and endocrine func-
tions. The process of forming new blood vessels from the
already existing vessels is called angiogenesis. This process
is often present in physiology as part of tissue healing, de-
velopment of the placenta and endometrium [4]. Further-
more, it is crucial in the pathophysiology of such diseasesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Level MMP-2 in group II before surgery, in 7 and 30 days after surgery to Control Group.
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psoriasis [8]. The role of angiogenesis in the biology of
neoplasm is extremely interesting [9]. A search is under-
way for a substance that can stimulate angiogenesis either
directly for example by angiogenic cytokines, or indirectly
through such agents as extracellular matrix (ECM) de-
grading enzymes [10].
Metalloproteinases are proteolytic enzymes responsible
for the degradation of ECM proteins and the basal mem-
brane of the vessels. They play a significant part in the
development of many neoplastic diseases and diseases of
the connective tissues [11]. Two of the most important
enzymes from this group are matrix metalloproteinase-2
(gelatinase A) MMP-2 and matrix metalloproteinase-9
(gelatinase-B), whose substrates are collagens type I, IV,
V, VII, X, XI, XIV, gelatine, fibronectin, laminin, agrecan,
and casein. Due to the diversity of the substances af-
fected by this enzyme, its activity level is responsible forFigure 2 Level MMP-9 in group II before surgery, in 7 and 30 days afthe course of many pathological processes in humans
[12]. The substances that hamper angiogenesis are tissue
inhibitors of metalloproteinases (TIMPs). TIMPs com-
prise the family of four proteins: multifunctional com-
pounds which, despite their inhibiting impact on MMPs,
play a significant role in maintaining a balance between
synthesis and ECM proteins in various physiological and
pathological processes. TIMP-1 and TIMP-2 are highly
specific to MMP-2 and MMP-9 [13].
In the literature there are few reports on the concen-
tration values of metalloproteinases and their tissue
inhibitors in serum of the pancreatic tumor patients
[14,15]. Similarly, not many reports describe the concen-
tration of these enzymes and their inhibitors due to the
advanced stage of a pancreatic tumor.
The aim of the study was to evaluate the concentra-
tion of proteolytic enzymes MMP-2 and MMP-9, and
their tissue inhibitors TIMP-1 and TIMP-2 in the bloodter surgery to Control Group.
Table 1 Level TIMP-1 and (±) standard deviation by
patients with pancreatic tumors in all groups before
surgery and statistical significance (P)
TIMP-1 (ng/mL) Mean (x) Standard deviation P vs. CG
I 202.73 ± 74.60 0.015
II 143.31 ± 30.52 P >0.05
III 189.63 ± 45.66 P >0.05
IV 207.00 ± 33.28 0.008
CG 133.20 ± 18.39 X
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as well as providing answers to the following questions:
a. Can any changes in concentration of the studied
factors in blood be observed?
b. Can the concentration of these factors in blood be
treated as a preoperative differential parameter for
benign and malignant pancreatic tumors?
c. Does the concentration of MMPs and TIMPs in
blood correlate with one another as well as with the
clinical severity of a pancreatic tumor?
d. Does the removal of a pancreatic tumor affect the
concentration change of these factors? Can a
possible difference in concentrations have an
influence on the prognosis of a pancreatic tumor?
Methods
The study was conducted on 134 Caucasian patients
aged 54 to 76 years (mean age, 59 years) with pancreatic
tumors (118 men, 16 women), who underwent surgical
treatment in the Department of Thoracic Surgery,
General and Oncological Surgery, Medical University of
Lodz, between the years 20072011. Each studied patient
was subject to pancreatic and biliary surgery.
The studied patients were divided into four groups de-
pending on the type of tumor, which was classified
through the TNM system (under the 7th edition of the
American Joint Committee of Cancer – cancers in
groups I-III) before and after surgery on the basis of the
perioperative picture, the range of surgery, and follow-
up within 1 to 2 years after the procedure:
1. Group I (n=29): patients with pancreatic cancer at
advanced stages I and II of severity on the day of the
operation (surgical resection of the pancreas), no
recurrence or metastases to distant organs within 2
years following surgery;
2. Group II (n=44): patients with pancreatic cancer at
advanced stages III and IV of severity (unresectable
tumors - bypass anastomoses and/or laparotomy
performed);
3. Group III (n=37): patients with pancreatic cancer at
advanced stages I and II of severity on the day of theTable 2 Level TIMP-1 and (±) standard deviation by patients
surgery and statistical significance (P)
TIMP-1 (ng/mL) Mean (x) Standard deviation
I 223.74 ± 69.00
II 141.00 ± 32.19
III 210.68 ± 45.18
IV 211.64 ± 29.19
CG 133.20 ± 18.39operation, recurrence or metastases to distant
organs within 2 years after surgery observed;
4. Group IV (n=24): patients with benign inflammatory
tumors, not malignant tumors often due to chronic
pancreatic inflammation (resections of the pancreas).
On histopathological investigation, pancreatic adeno-
carcinoma was diagnosed in the patients from groups I
to III. The study excluded the patients with other histo-
logical forms of the tumor, such as neuroendocrine
tumors (GEP-NET) and intraductal papillary mucinous
neoplasms (IPMN).
The control group consisted of 30 healthy volunteers,
men aged 45 to 68 years (mean age, 56 years) who were
randomized from the patients with excluded neoplastic
changes and inflammatory processes, and who under-
went planned surgery due to non-inflammatory chole-
cystolithiasis. All of these patients underwent routine
bedside examinations (physical, labs) and went through
a series of abdominal cavity examinations as well as
USG, ERCP, MRCP, and/or MRI.
The mean blood concentrations of MMP-2, MMP-9,
and their tissue inhibitors TIMP-1 and TIMP-2 were de-
termined prior to surgery, on the 7th and 30th day of
follow-up. Blood was obtained by standard blood tests.
It was centrifuged and stored at −60°C. The patients
were fasting at the time of sampling. The MMP-2 and
MMP-9 level in blood was determined using the
standard immunoenzymatic ELISA method by means of
Amersham Biosciences (sensitivity <0.37 ng/mL; intrase-
rial accuracy (CV) 5.6%; and interserial accuracy (CV)
10%). The TIMP-1 and TIMP-2 level in blood waswith pancreatic tumors in all groups in 30 days after
P vs. GI P vs. GII P vs. GIII P vs. GIV
X 0.002 P >0.05 P >0.05
0.002 X <0.001 <0.001
P >0.05 <0.001 X p>0.05
P >0.05 <0.001 P>0.05 X
<0.001 <0.05 <0.001 <0.001
Figure 3 Level TIMP-1 in group I before surgery, in 7 and 30 days after surgery to Control Group.
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method by Amersham Biosciences (sensitivity <3.0 ng/
mL; intraserial accuracy (CV) 3.9%; and interserial ac-
curacy (CV) 4.8%).
To determine the optical density of each well immedi-
ately, a microplate reader set to 450 nm was used. If the
wavelength correction was available, it was set to 540
nm or 570 nm. If the wavelength correction was not
available, readings were subtracted at 540 nm or 570 nm
from the readings at 450 nm. This subtraction was
corrected for optical imperfections in the plate by means
of Metertech 960 (Bellco Biomedica Company).
All patients signed informed consent forms and ethical
approval was obtained from the Bioethics Department of
the Medical University of Lodz, Poland (reference RNN/
54/10/KB).
The statistical analysis was performed with SPSS
(Statistical Package for Social Science, version 16.0) for
Windows. Data are shown as mean ± standard deviation
and 95% confidence intervals where applicable. The
mean differences among the groups were evaluated by
one-way ANOVA. P values <0.05 were considered statis-
tically significant.
The work was financed under the Medical University
own study no. 502-03/5-138-01/502-54-017.Table 3 Level TIMP-2 and (±) standard deviation by
patients with pancreatic tumors in all groups before
surgery and statistical significance (P)
TIMP-2 (ng/mL) Mean (x) Standard deviation P vs. CG
I 136.53 ± 25.85 P >0.05
II 142.56 ± 28.82 0.03
III 129.21 ± 25.70 P >0.05
IV 125.71 ± 24.27 P >0.05
CG 110.20 ± 10.15 XResults
The study has evaluated the active forms of MMP-2 and
MMP-9. The highest mean concentration of MMP-2 be-
fore surgery was in group II - 1,347.12 ± 168.6 (95% CI
1,257.3-1,436.9) ng/mL, whereas the lowest mean con-
centration was noticed in group I - 1,255.26 ± 140.6
(95% CI 1,187.51,323.0) ng/mL. Although these results
were higher than in the control group, they were not
statistically significant (P >0.05).Prior to the operation, as well as in the follow-up 1
week later, no statistically significant differences in the
mean concentrations of MMP-2 were found in any of
the studied groups when compared to the control group
(Figure 1). However, 1 month after surgery, the highest
mean concentration of MMP-2 measured in group II
was 1,478.25 ± 330.1 (95% CI 1,302.4-1,654.2) ng/mL,
which was significantly higher than in the control group
and in the other groups (P <0.05).
The highest mean concentration of MMP-9 before
surgery was in group I: 135.68 ± 43.7 (95% CI 114.6-
156.7) ng/mL. The lowest mean concentration was in
group IV: 94.07 ± 45.8 (95% CI 67.7-120.5) ng/mL. All
the results were significantly higher than in the control
group (P <0.05). Seven days after surgery the mean con-
centrations of MMP-9 in groups I, II, and III were sig-
nificantly higher than in the control group (P <0.05).
The results between the groups were not significantly
different. However, on the 30th day following the oper-
ation, the mean concentration of MMP-9 in each group
was not significantly different from the control group.
No statistically significant differences among the groups
were found either. In group II only, the level of MMP-9
was significantly higher than in the control group before
and after surgery P <0.05 (Figure 2).
Table 4 Level TIMP-2 and (±) standard deviation by patients with pancreatic tumors in all groups in 30 days after
surgery and statistical significance (P)
TIMP-2 (ng/mL) Mean (x) Standard deviation P vs. GI P vs. GII P vs. GIII P vs. GIV
I 128.95 ± 23.82 X P >0.05 P >0.05 P >0.05
II 118.56 ± 19.84 P >0.05 X P >0.05 P >0.05
III 132.84 ± 26.96 P >0.05 P >0.05 X P >0.05
IV 158.78 ± 30.27 0.014 <0.001 0.042 X
CG 110.20 ± 10.15 P >0.05 P >0.05 P >0.05 0.005
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TIMP-1 was higher in patients with pancreatic tumors
than in the control group (Table 1). The highest mean
concentration of TIMP-1 was observed in group IV
(207.00 ± 33.4 (95% CI 187.8-226.2) ng/mL) in patients
with inflammatory tumors before surgery. The lowest
mean concentration was found in group II: 143.31 ±
30.5 (95% CI 127.1-159.6) ng/mL. Only the mean con-
centrations of TIMP-1 in groups I and IV were signifi-
cantly higher (P <0.05) than in the control group. In a 7-
day follow-up, the mean concentrations of TIMP-1 in
each group were significantly higher than in the control
group (P <0.05). Only the mean concentration of TIMP-
1 in group II (152.50 ± 34.7 (95% CI 134.0-171.0) ng/
mL) was statistically different from the results of the
remaining groups (P <0.01). Similarly, in the 30-day
follow-up (Table 2) the mean concentrations in each
group were significantly higher than those of the control
group, and the mean concentration of TIMP-1 in group
II was significantly different from the mean concentra-
tions in the other groups (P <0.05). Before and after sur-
gery, a significantly higher level of TIMP-1 was noticed
only in group I P <0.05 (Figure 3).
Prior to surgery, the level of TIMP-2 in the pancreatic
tumor patients was higher than in the control group
(Table 3). Before the operation, the highest mean con-Figure 4 Level TIMP-2 in group II before surgery, in 7 and 30 days afcentration of TIMP-2 was observed in group II (142.56
± 28.8 (95% CI 127.2-157.9) ng/mL) and was statistically
significant (P <0.05). The mean concentrations of TIMP-
2 in the other groups did not differ significantly from
those found in the control group. Seven days after the
operation, in each group, the mean concentrations of
TIMP-2 did not differ significantly from the control
group. At the 30-day follow-up, the highest mean con-
centration of TIMP-2 (158.78 ± 30.3 (95% CI 141.3-
176.3) ng/mL) was noticed in group IV. This result was
significantly higher than the control group (Table 4) and
significantly higher than in the other groups (P <0.05).
The changes of TIMP-2 level in relation to the control
group before and after surgery are depicted in Figure 4.
The correlation between MMP-9 and TIMP-2 was sta-
tistically significant only in group II before, and 30 days
after, surgery (P <0.05). This is shown in Figures 5 and 6
and Tables 5 and 6.
Discussion
Pancreatic cancer, its diagnostics, and therapy are the sub-
ject of many meta-analyses [16-18]. The dynamics of solid
tumor growth often results in a late diagnosis, which, con-
sequently, hampers the radical treatment possibilities.
Therefore, the cancer studies largely emphasize the detec-














Correlation MMP-9 and TIMP-2 before surgery in group II
Figure 5 Correlation MMP-9 and TIMP-2 in group II before surgery.
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were treated in our Department. Surgery was implemen-
ted in 153 cases. The rest of the patients were subject to
endoscopy, diagnostic laparotomy, or palliative treat-
ment. The work covered 134 patients, out of whom only
29 (21.6%; group I) could undergo therapeutic surgery,
whose therapeutic effect was confirmed by a 2-year
follow-up without recurrence or metastasis of tumor.
The observation of the patients is still ongoing and the
complete data can be presented after a 5-year follow-up
period.
The role of proteolytic enzymes and their inhibitors
has already been affirmed in the growth of many tumors,
such as cancer of the esophagus, stomach, large intes-















Correlation MMP-9 and TIMP-2 in
Figure 6 Correlation MMP-9 and TIMP-2 in group II in 30 days after sthe role of angiogenesis and the factors participating in
the ECM degradation in the pathology of pancreatic tu-
mors is not fully recognized.
The cytokines taking part in ECM degradation, which
were observed in the blood of pancreatic tumor patients,
are MMP-2 and MMP-9. The study showed that the
concentration of MMP-2 was higher in each studied
group with reference to the control group, before and
after surgery. However, statistically significant growth
was found only on the 30th day after surgery in the pa-
tients with advanced stages III and IV of pancreatic can-
cer, who had undergone palliative procedures.
In the evaluation of MMP-9, a significantly higher
concentration of this factor was found in the groups
with malignant neoplasm, while in the group with160 180 200 220 240
MP-9
 30 days after surgery in group II
urgery.
Table 5 Correlation MMP-9 and TIMP-2 in group II and
correlation index rang ρ before surgery
Correlation group II MMP-9 & TIMP-2
Correlation index rang ρ 0.5
P 0.04613
N 19
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nificantly lower than in the control group. Similar results
have been presented by other authors [14,27].
In the evaluation of tissue inhibitors of metallopro-
teinases, significantly higher mean concentrations of
TIMP-1 were observed before the planned surgery in
the groups with benign changes or lower advanced
stages of pancreatic cancer. Seven and 30 days following
the tumor excision, the significantly higher concentra-
tions were still present. In group II of the patients with
highly advanced inoperable cancer, no statistically sig-
nificant differences from the control group were found.
However, the statistically significant growth of the mean
concentration of TIMP-1 occurred after surgery in the
patients with resectable tumors, where recurrence or
metastases were noticed.
In the analysis of the next anti-angiogenic factor,
TIMP-2, the mean concentration of this cytokine was
higher in each group and at each of the three time
periods when compared with the control group. A
significantly higher level of this inhibitor can be very
meaningful in the patients with unresectable cancer of
the pancreas before surgery. In the remaining groups,
before the operation, no changes in the concentration of
TIMP-2 were found.
The TIMP expression is not very well investigated in
neoplastic diseases. Nowadays the activity of TIMPs is
vital in pathogenesis of the cancer of the esophagus,
stomach, intestine, and lungs [28]. Up to now, however,
the role of TIMP-1 as a predictive factor has been con-
firmed only in the case of cancer of the esophagus and
the stomach [29].
In lung cancer, a detailed analysis of MMPs and
TIMPs was presented by Iniesta et al., who demon-
strated that MMP-9 can be used as a factor in poten-
tially unfavorable clinical evolution and TIMP-1 bears
features of an independent prognostic factor in lung
cancer [30]. The evaluation of the studied cytokines mayTable 6 Correlation MMP-9 and TIMP-2 in group II and
correlation index rang ρ in 30 days after surgery
Correlation group II MMP-9 & TIMP-2
Correlation index rang ρ 0.76
P 0.00059
n 19facilitate their future use as neoplastic markers, which,
in turn, could allow the advanced stage of pancreatic
cancer to be determined before surgery and prognosti-
cate the course of the disease.
The knowledge of whether the concentration and/or
activity of these studied factors in blood may be treated
as differential parameters in benign and malignant pan-
creatic tumors before surgery could help surgeons to as-
sess their patients preoperatively. In the future, this
might contribute to an early diagnosis and more suc-
cessful treatment of a pancreatic cancer.
Conclusions
1. The mean concentration of MMP-2 and MMP-9 in
blood of pancreatic cancer patients is significantly
higher than in the control group.
2. Before surgery, a significantly higher mean
concentration of MMP-9 is seen in the serum of the
patients with pancreatic cancer than that of healthy
people, and the significantly lower concentration of
this enzyme in patients with inflammatory
pancreatic tumors, could be diagnostically
meaningful in the differentiation of benign and
malignant changes.
3. The significantly higher mean concentration of
TIMP-1 in blood of the patients with pancreatic
tumors at the low advanced stages and significantly
higher mean concentration of TIMP-2 in blood of
the patients from the other groups and the control
group could have a prognostic value in this disease
entity.
4. The reciprocal strong positive correlation of MMP-9
and MMP-2 before and after surgery can be
significant in the prognosis of the neoplastic
advanced stage.
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